Page 52 - 南京医科大学自然版
P. 52

第46卷第7期
               ·998 ·                            南 京    医 科 大 学 学         报                        2026年7月


                   nervous system,1990⁃2021:a systematic analysis for the  longitudinal mediation of cognitive function in patients
                   Global Burden of Disease Study 2021[J]. Lancet Neurol,  with Parkinson’s disease[J]. Front Aging Neurosci,

                   2024,23(4):344-381                                2025,17:1513373
             [2] MENG D,JIN Z,WANG Y,et al. Longitudinal cognitive  [14]SCHROEDERS U,ZIMMERMANN J,WICKE T,et al.
                   changes in patients with early Parkinson’s disease and  Dynamic interplay of cognitive functioning and depressive
                   neuropsychiatric symptoms[J]. CNS Neurosci Ther,2023,  symptoms in patients with Parkinson’s disease[J]. Neuro⁃
                   29(8):2259-2266                                   psychology,2022,36(4):266-278
             [3] DALRYMPLE W A,TRACH S K,FLANIGAN J L,et al.    [15]LEE B,YOUNG C B,CAI W,et al. Dopaminergic modula⁃
                   Psychiatric predictors of quality of life in Parkinson’s dis⁃  tion and dosage effects on brain state dynamics and working
                   ease:a three ⁃ year longitudinal study[J]. J Neurol Sci,  memory component processes in Parkinson’s disease[J].
                   2024,466:123248                                   Nat Commun,2025,16(1):2433
             [4] DENG X,SAFFARI S E,XIAO B,et al. Disease progres⁃  [16]COSTELLO H,SCHRAG A E,HOWARD R,et al. Disso⁃
                   sion in Parkinson’s disease patients with mild cognitive  ciable effects of dopaminergic medications on depression
                   impairment:5⁃year longitudinal study from the early Par⁃  symptom dimensions in Parkinson disease[J]. Nat Ment
                   kinson’s disease longitudinal Singapore(PALS)cohort[J].  Health,2024,2(8):916-923
                   Aging(Albany NY),2024,16:11491-11500         [17]DALRYMPLE⁃ALFORD J C,MACASKILL M R,NAKAS
             [5] LE HERON C,HORNE K L,MACASKILL M R,et al.           C T,et al. The MoCA:well⁃suited screen for cognitive im⁃
                   Cross ⁃ sectional and longitudinal association of clinical  pairment in Parkinson disease[J]. Neurology,2010,75
                   and neurocognitive factors with apathy in patients with  (19):1717-1725
                   Parkinson disease[J]. Neurology,2024,102(12):e209301  [18]KUKKLE P L,KALIA L V,HABIB A,et al. Levodopa
             [6] SONG T,XIANG L,LIU Y,et al. Survival and related fac⁃  equivalent daily dosage:geographical variations and real⁃
                   tors in patients with Parkinson’s disease:a multicenter  life modules in Parkinson’s disease[J]. Mov Disord Clin
                   prospective cohort study in China[J]. J Neurol,2026,273  Pract,2024,11(11):1388-1395
                  (1):69                                        [19]ZHU K,VAN HILTEN J J,MARINUS J. Associated and
             [7] SU W,LIU H,JIANG Y,et al. Correlation between depres⁃  predictive factors of depressive symptoms in patients with
                   sion and quality of life in patients with Parkinson’s dis⁃  Parkinson’s disease[J]. J Neurol,2016,263(6):1215-
                   ease[J]. Clin Neurol Neurosurg,2021,202:106523    1225
             [8] ZHU X,GAN J,WU N,et al. The simultaneous presence  [20]OWENS⁃WALTON C,NIR T M,AL⁃BACHARI S,et al.
                   of demoralization,apathy,and depression has a detrimen⁃  A worldwide study of white matter microstructural altera⁃
                   tal impact on both cognitive function and motor symptoms  tions in people living with Parkinson’s disease[J]. NPJ
                   in Parkinson’s disease patients[J]. Front Psychiatry,  Parkinsons Dis,2024,10(1):151
                   2024,15:1345280                              [21]BROWN G,HAKUN J,LEWIS M M,et al. Frontostriatal
             [9] XU J,WANG Y,LI Y,et al. Clinical characteristics and  and limbic contributions to cognitive decline in Parkin⁃
                   risk factors of depression in prodromal Parkinson’s dis⁃  son’s disease[J]. J Neuroimaging,2023,33(1):121-133
                   ease[J]. Front Neurosci,2026,19:1708805      [22]FERNANDES M,PIERANTOZZI M,STEFANI A,et al.
             [10]GALLAGHER J,GOCHANOUR C,CASPELL⁃GARCIA              Frequency of non ⁃ motor symptoms in Parkinson’s pa⁃
                   C,et al. Long⁃term dementia risk in parkinson disease[J].  tients with motor fluctuations[J]. Front Neurol,2021,12:
                   Neurology,2024,103(5):e209699                     678373
             [11]AARSLAND D,BRONNICK K,WILLIAMS⁃GRAY C,et       [23]DIEDERICH N J,SAUVAGEOT N,PIERI V,et al. The
                   al. Mild cognitive impairment in Parkinson disease:a mul⁃  clinical non⁃motor connectome in early Parkinson’s dis⁃
                   ticenter pooled analysis[J]. Neurology,2010,75(12):  ease[J]. J Parkinsons Dis,2020,10(4):1797-1806
                   1062-1069                                    [24]KOBAK T E,ARI B C. Mild cognitive impairment in pa⁃
             [12]GONG S,WANG T,TANG R,et al. Prevalence,associat⁃    tients with Parkinson’s disease and the analysis of associ⁃
                   ed factors and impact of mild cognitive impairment in hos⁃  ated factors[J]. Neurol Res,2023,45(12):1161-1168
                   pitalized older adults with Parkinson’s disease:a cross⁃  [25]YIN J,JOHN A,CADAR D. Bidirectional associations of
                   sectional study[J]. Front Aging Neurosci,2025,17:  depressive symptoms and cognitive function over time[J].
                   1693417                                           JAMA Netw Open,2024,7(6):e2416305
             [13]XU Y,CHEN D,DONG M,et al. Bidirectional relation⁃  [26]BIUNDO R,WEIS L,BOSTANTJOPOULOU S,et al.
                   ship between depression and activities of daily living and                 (下转第1010页)
   47   48   49   50   51   52   53   54   55   56   57